Q1 FY27

Earnings Presentation

31st July 2026

NSE:SUNPHARMA | BSE:524715 |
Bloomberg:SUNP IN |
Reuters:SUN.BO

WWW.SUNPHARMA.COM

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Sun Pharmaceutical Industries Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Performance Highlights

Q1FY27 Performance	Innovative Medicine focus	Financial Prudence
Sales Growth at 10.1%	**Global Innovative Medicines continues to deliver strong growth at 12.8%** for the quarter	Strong balance sheet, with **Net Cash position of US$ 3.4 bn**
EBITDA Margin for the quarter at 28.9%	Innovative Medicines remain key to our strategy	
With our presence in 100+ countries, Sun Pharma continues to solidify global reach		

Financial Snapshot

(₹ mn)	Q1FY27	Q1FY26	Y-o-Y
Sales	**1,51,836**	1,37,861	10.1%
Gross Margin %	**80.5%**	79.6%	
EBITDA	**44,177**	43,017	2.7%
EBITDA%	**28.9%**	31.1%	
Reported PAT	**28,948**	22,786	
Adjusted PAT	**30,894**	29,961	3.1%
EPS	**12.1**	9.5	

Q1FY27 : Sales of ₹ 151.8 bn, 10.1% growth over last year, with Profit After Tax of ₹ 28.9 bn

Revenue Snapshot



Note: Numbers shown are Sales excluding Other Operating Revenue

Innovative Medicines

Sales (US$ mn)



- ✓ Growth of 12.8% in Q1FY27, driven by both US & international markets
- ✓ Global Innovative Medicines sales forms 21.8% of total consolidated sales for the quarter

India Formulations

Sales (₹ mn)



Sustained Market Share* Growth



- ✓ In Q1, India formulations recorded growth of 16%, led by CVD, CNS, Gastro-Ortho segments
- ✓ Sustained market share growth; 0.3pp gain over the year to reach 8.5%
- ✓ India Formulations forms 36.1% of total consolidated sales for the quarter

* Market Share as per Pharmarack MAT-Jun’26

US Formulations

Sales (US$ mn)







- ✓ US Formulations declined by 9.7% in Q1FY27, to US$ 427 mn.
- ✓ Ilumya, Cequa & Odomzo led growth for IM, offset by a decline in Generics, including lenalidomide
- ✓ For Q1FY27, US Formulations forms 26.6% of total consolidated sales for the quarter

Emerging Markets Formulations

Sales (US$ mn)



Focus Markets

- Romania
- Brazil
- South Africa
- Mexico

- ✓ Emerging Markets recorded Q1FY27 Revenue of US$ 311 mn, 4.2% higher than last year
- ✓ Emerging Markets Formulations form 19.4% of total consolidated sales for the quarter
- ✓ Innovative Medicines portfolio continues to drive growth in Emerging Markets

Rest of World Formulations

Sales (US$ mn)



Focus Markets

- Western Europe
- Canada
- Japan
- Australia & NZ

✓ RoW Formulations recorded Q1FY27 Revenue of US$ 218 mn

✓ RoW Formulations form 13.6% of total consolidated sales for the quarter

R&D Update

Candidate	Indication	Current phase	Next milestone
Ilumya	psoriatic arthritis	Supplement filed with US FDA	PDUFA Date: Oct-26
Fibromun	soft tissue sarcoma	Phase 2 completed	Start of Phase 3
	glioblastoma	Phase 2	Regulatory filing
GL0034	type 2 diabetes	Phase 2	Topline data during 2HCY27
Nidlegy™ (EU, ANZ rights with Sun)	locally advanced melanoma	Filing with EMA	Approval and launch
	locally advanced BCC	Phase 2	Regulatory filing
	locally advanced cSCC	Phase 2	Regulatory filing
Candidate for partnering			
MM-II	pain in osteoarthritis	Phase 2 completed	To enter partnership for commercialization

- ✓ In Q1FY27, R&D investments were at 5.4% of sales
  - ✓ Of the total R&D spend, 30% was for Innovative Medicines R&D

Organon Acquisition Update

1 Signed definitive docs with Organon on 27th April 2026

2 Ongoing deal closure

- US HSR & a few other countries' approvals received
- Organon received Shareholders' approval on 23rd July

3 Sun and Organon will continue to work as independent entities till deal closure.

4 Integration Planning post-closing

- Integration Management Office working on Day 1 preparedness.

5 Indicative closure of proposed transaction by Q4FY27

For more information, please contact

Investors

Dr. Abhishek Sharma
Tel : +91 22 4324 4324, Xtn 2929
Tel Direct +91 22 4324 2929
abhi.sharma@sunpharma.com

Corporate Address

SUN HOUSE, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063

NSE:SUNPHARMA, BSE: 524715, Reuters: SUN.BO, Bloomberg: SUNP IN
CIN: L24230GJ1993PLC019050
www.sunpharma.com